Immunome Inc.
Immunome, Inc. (Nasdaq: IMNM) is a biotechnology company developing targeted therapies for cancer, including antibody-drug conjugates (ADCs) and radioligand therapies. Its pipeline includes three clinical-stage and three preclinical assets. Varegacestat, an oral gamma secretase inhibitor acquired from Ayala… From the company’s description.
In fiscal 2025, Immunome Inc. reported revenue of $6.94M, down 23.2% from fiscal 2024, and a net loss of $212.39M. Its operating margin was −3228.8%, and operations used $190.92M in cash. Over the twelve months to Jun 30, 2026, revenue was $0.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Immunome Inc. does
In the company’s own words
Immunome, Inc. (Nasdaq: IMNM) is a biotechnology company developing targeted therapies for cancer, including antibody-drug conjugates (ADCs) and radioligand therapies. Its pipeline includes three clinical-stage and three preclinical assets. Varegacestat, an oral gamma secretase inhibitor acquired from Ayala Pharmaceuticals in 2024, is being developed for desmoid tumors; the company reported positive Phase 3 results in 2025 and is preparing a regulatory submission. IM-1021 is a ROR1-targeted ADC in a Phase 1 trial for solid tumors and B-cell lymphomas, while IM-3050 is a FAP-targeted radioligand therapy planned for Phase 1 evaluation. The company’s preclinical pipeline includes three solid-tumor ADCs, IM-1617, IM-1340 and IM-1335, and additional early-stage ADC programs. Its ADC research uses proprietary HC74, a topoisomerase 1 inhibitor payload, and focuses on novel or underexplored targets. Immunome’s operations center on discovering and developing oncology medicines, with potential commercialization of its products also part of its strategy.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOTHELL, WA
- Fiscal year end
- December
- CIK
- 1472012
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Immunome Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Immunome Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Immunome Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Immunome Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Immunome Inc.'s last four quarterly filings that the numbers alone won't show?”